Dr. Elisa Krill-Jackson, MD

Dr. Krill-Jackson practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Krill-Jackson's NPI, 1427046085, was assigned on October 7, 2005. Dr. Krill-Jackson graduated from University Of Michigan Medical School in 1990. Dr. Krill-Jackson holds Florida license ME66352.

Dr. Krill-Jackson's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Krill-Jackson's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Krill-Jackson is also affiliated with Boca Raton Regional Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Krill-Jackson to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Krill-Jackson practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Krill-Jackson's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Krill-Jackson is board certified in medical oncology by the American Board of Internal Medicine. Dr. Krill-Jackson is licensed in Florida.

Dmand AI lists breast cancer, chronic leukemia, colorectal cancer, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Krill-Jackson treats.

CMS data shows 810 Medicare services from Dr. Krill-Jackson across 3 procedure codes in 2024, all of them office visits, for 343 Medicare patients. Medicare paid $49,873 for them.

CMS counts 343 Medicare patients who saw Dr. Krill-Jackson in 2024. The largest group is 65 to 74, with 145 patients. 75% of them have cancer, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Krill-Jackson's median patient age at 71, with 95% women.

In 2024, Dr. Krill-Jackson wrote 710 Medicare Part D claims for 203 patients. 80% of them were for generic drugs. CMS names the drug for 579 of them, across 18 drugs with 11 or more claims each, at $1,810,398 in total drug cost. In 2023, CMS named 356 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Krill-Jackson for performance year 2024, reported as part of a group. Dr. Krill-Jackson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Krill-Jackson as offering telehealth.

Dmand AI links 5 papers to Dr. Krill-Jackson, published from 2010 to 2013. The most frequent topics are Breast Neoplasms, Antibodies, Monoclonal, Humanized and Antineoplastic Combined Chemotherapy Protocols. Dr. Krill-Jackson's most frequent co-authors are Judith Hurley, MD, Adam M. Brufsky, MD and Michael S. Frontiera, MD.

Dmand AI links Dr. Krill-Jackson to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Cardiotoxicity, Neoplasm Metastasis and Breast Neoplasms, Male. Open Payments lists research payments to Dr. Krill-Jackson that name 1 trial.

CMS Open Payments shows 1,499 general payments to Dr. Krill-Jackson from 61 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 51% of the total. Eli Lilly and Company paid the most, $65,934. It also lists 2 research payments totaling $2,261 from 2022 to 2023, naming 1 clinical trial.

Dmand AI lists 3 awards for Dr. Krill-Jackson, most recently Regional Top Doctor in 2014.

Dr. Krill-Jackson graduated from University Of Michigan Medical School in 1990. Dr. Krill-Jackson is a member of ACP and ASCO.

Dr. Krill-Jackson is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.